CVS Health Corp vs PulteGroup, Inc. — how do they compare? CVS Health Corp trades at $86.85 (market cap $112.49B), while PulteGroup, Inc. trades at $111.89 (market cap $21.40B). The key difference: CVS Health Corp is far larger — about 5.3× PulteGroup, Inc.'s market cap, and CVS Health Corp pays the higher dividend (3.02%). Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and PulteGroup, Inc. for 91 Days on average.
| CVS | PHM | |
|---|---|---|
Market Cap | $112.49B | $21.40B |
Volume | 8,467,392 | 2,220,826 |
Sector | Health | Consumer Cyclical |
52-Week High | $110.60 | $142.56 |
52-Week Low | $70.08 | $110.11 |
Typical Hold Time | 83 Days | 91 Days |
Enterprise Value | $174.83B | $21.81B |
Dividend Yield | 3.02% | 0.93% |
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.80, up 1.59% today, with strong analyst support (85% buy ratings) and a $111.20 consensus price target suggesting 27% upside. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $2.58 surpassing the $1.87 estimate. Revenue growth remains solid, reaching $402.07B in 2025, though net margins compressed to 1.18%. The technical picture shows bullish momentum with current price near key support at $87.
CVS presents a compelling value opportunity with attractive valuation multiples (P/E 23.21, P/S 0.27) and dividend stability, but faces margin pressure from healthcare cost trends. The stock's upside depends on maintaining earnings momentum amid reimbursement challenges and regulatory scrutiny highlighted in recent legal investigations.
PulteGroup (PHM) trades at $113.53, down 2.22% amid broader market weakness. The stock shows bearish technical signals with RSI at oversold levels near 19.42, while fundamentals remain solid with a P/E of 11.47 and strong profitability metrics including 14.9% ROE. Recent earnings show mixed results with Q2 2026 beating expectations but Q4 2025 and Q1 2026 missing estimates. The company maintains positive cash flow generation with $355.10M net cash flow in 2025.
PHM presents a value opportunity with attractive valuation multiples, though facing headwinds from rising mortgage rates impacting the housing sector. Analyst consensus targets $139.80 (23% upside) with 45% buy ratings, but technical indicators suggest near-term pressure. Key risks include housing market sensitivity to interest rates and margin compression from recent earnings misses.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →PulteGroup Inc is one of the largest homebuilders in the United States, operating in 40 markets across 23 states. The company mainly builds single-family detached homes (85% of unit sales) and offers products to entry-level, move-up, and active-adult buyers. PulteGroup offers homebuyers mortgage financing and title agency services through its financial services segment. The company is headquartered in Atlanta.
Read more on PHM →